Evofem Biosciences (EVFM) Scheduled to Post Earnings on Wednesday

Evofem Biosciences (NASDAQ:EVFMGet Rating) is scheduled to post its quarterly earnings results after the market closes on Wednesday, May 4th. Analysts expect Evofem Biosciences to post earnings of ($0.19) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Evofem Biosciences (NASDAQ:EVFMGet Rating) last issued its quarterly earnings results on Thursday, March 3rd. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.10). The company had revenue of $3.57 million during the quarter, compared to the consensus estimate of $3.52 million. During the same quarter last year, the firm posted ($0.50) earnings per share. On average, analysts expect Evofem Biosciences to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of EVFM stock opened at $0.18 on Wednesday. The stock has a market cap of $32.96 million, a price-to-earnings ratio of -0.11 and a beta of -0.37. The business’s fifty day moving average is $0.36 and its 200 day moving average is $0.45. Evofem Biosciences has a twelve month low of $0.17 and a twelve month high of $1.55.

Several equities research analysts recently weighed in on the company. Morgan Stanley upped their price target on Evofem Biosciences from $0.53 to $0.57 and gave the stock an “underweight” rating in a research note on Tuesday, April 12th. HC Wainwright reissued a “buy” rating and issued a $2.00 target price on shares of Evofem Biosciences in a research note on Monday, January 31st.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. UBS Group AG grew its stake in shares of Evofem Biosciences by 441.4% in the third quarter. UBS Group AG now owns 46,432 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 37,855 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Evofem Biosciences by 148.0% in the third quarter. Goldman Sachs Group Inc. now owns 89,997 shares of the biotechnology company’s stock worth $67,000 after acquiring an additional 53,707 shares during the last quarter. Morgan Stanley grew its stake in shares of Evofem Biosciences by 29.6% in the first quarter. Morgan Stanley now owns 132,016 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 30,114 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Evofem Biosciences by 5,822.7% in the fourth quarter. JPMorgan Chase & Co. now owns 132,490 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 130,253 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Evofem Biosciences in the fourth quarter worth $53,000. 16.16% of the stock is currently owned by hedge funds and other institutional investors.

About Evofem Biosciences (Get Rating)

Evofem Biosciences, Inc, a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women.

Recommended Stories

Earnings History for Evofem Biosciences (NASDAQ:EVFM)

Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.